On June 27, 2023, the signing ceremony of the Memorandum of Understanding between Central Pharmaceutical Company CPC1, JSC and Medsintez Plant LLC was held at the headquarters of Central Pharmaceutical Company CPC1, JSC in Hanoi. The ceremony was attended by representatives of the management of CPC1, the Medsintez Plant, Pharmviet JSC and the Embassy of the Russian Federation in Vietnam.

 

 

Over 50 years of development, CPC1 has proven its brand value as one of the leading drug and medical device distribution companies in Vietnam. Over 50% of the company’s various clients are state medical institutions. In order to continuously utilize and develop new products, CPC1 wishes to expand cooperation with partners, i.e., corporations, large domestic and foreign pharmaceutical manufacturers.

 

The Medsintez Plant is one of the largest pharmaceutical enterprises in the Russian Federation; it was established in 2003 and specializes in developing and manufacturing medicines for human use, veterinary preparations, medical products and active pharmaceutical ingredients. The Medsintez Plant is one of the first plants in Russia that produce genetically engineered insulin with production capacities that meet 100% of the demand for insulin preparations used for medicinal purposes in Russia, including such preparations as Rosinsulin (solution, suspension, mix) and analogue insulins Rosinsulin Aspart and Rosinsulin Glargine. The Medsintez Plant also produces specialized medications, such as antiviral preparations, antibiotics, anticoagulant solutions, and recombinant follicle-stimulating hormone. The preparations are available in all dosage forms: pills, capsules, solution for infusion, emulsion, injection.

 

The quality and high process standards, as well as the equipment capacity of the Medsintez Plant have encouraged many international partners to cooperate for the production of medicines in Russia. The company has a need to establish a pharmaceutical company to manufacture antidiabetic preparations in the Socialist Republic of Vietnam, thus contributing to the provision of quality medical care for patients with diabetes in Vietnam, and aims to export to other countries in the region.

 

The purpose of signing a memorandum of understanding is to develop cooperation between CPC1 and the Medsintez Plant and mutual advancement in developing products for the present and future. The company plans to implement and complete (relatively soon) a project for construction of a plant that produces antidiabetic preparations in Vietnam and bring the products to the Vietnamese pharmaceutical market.